Abeona Therapeutics Inc (ABEO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.95 Million) by net assets ($159.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABEO equity to assets ratio to measure how much of total assets are equity-financed.
Abeona Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Abeona Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABEO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Abeona Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abeona Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vicore Pharma Holding AB (publ)
ST:VICO
|
-0.074x |
|
Radium Life Tech Co Ltd
TW:2547
|
0.025x |
|
PC1 Group JSC
VN:PC1
|
0.169x |
|
IVF Hartmann Holding AG
SW:VBSN
|
0.014x |
|
Waterstone Financial Inc
NASDAQ:WSBF
|
-0.002x |
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
0.051x |
|
Vetropack Holding SA
SW:VETN
|
0.157x |
|
JTL Industries Ltd
NSE:JTLIND
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Abeona Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Abeona Therapeutics Inc from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see ABEO market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $159.22 Million | $-76.33 Million | -0.479x | +62.32% |
| 2024-12-31 | $44.03 Million | $-56.02 Million | -1.272x | +49.04% |
| 2023-12-31 | $14.83 Million | $-37.01 Million | -2.496x | -53.63% |
| 2022-12-31 | $26.76 Million | $-43.48 Million | -1.625x | -4.84% |
| 2021-12-31 | $42.37 Million | $-65.67 Million | -1.550x | -353.87% |
| 2020-12-31 | $102.55 Million | $-35.02 Million | -0.341x | +3.01% |
| 2019-12-31 | $178.43 Million | $-62.82 Million | -0.352x | -20.67% |
| 2018-12-31 | $134.04 Million | $-39.11 Million | -0.292x | -116.40% |
| 2017-12-31 | $170.10 Million | $-22.93 Million | -0.135x | -2.67% |
| 2016-12-31 | $99.10 Million | $-13.01 Million | -0.131x | +14.67% |
| 2015-12-31 | $67.72 Million | $-10.42 Million | -0.154x | +53.99% |
| 2014-12-31 | $4.82 Million | $-1.61 Million | -0.335x | -494272.28% |
| 2013-12-31 | $-14.78 Million | $1.00K | 0.000x | -100.03% |
| 2012-12-31 | $-17.08 Million | $-3.96 Million | 0.232x | -46.41% |
| 2011-12-31 | $-17.61 Million | $-7.61 Million | 0.432x | +31.01% |
| 2010-12-31 | $-20.80 Million | $-6.86 Million | 0.330x | +296.06% |
| 2009-12-31 | $-26.99 Million | $-2.25 Million | 0.083x | -85.80% |
| 2008-12-31 | $-11.19 Million | $-6.56 Million | 0.586x | -91.75% |
| 2007-12-31 | $681.00K | $4.84 Million | 7.112x | +3491.03% |
| 2006-12-31 | $-9.89 Million | $-1.96 Million | 0.198x | -88.51% |
| 2005-12-31 | $-4.24 Million | $-7.30 Million | 1.723x | +26.45% |
| 2004-12-31 | $-6.66 Million | $-9.08 Million | 1.363x | +24.75% |
| 2003-12-31 | $-5.83 Million | $-6.36 Million | 1.092x | +106.21% |
| 2002-12-31 | $489.00K | $-8.60 Million | -17.577x | -2926.58% |
| 2001-12-31 | $9.08 Million | $-5.27 Million | -0.581x | -101.19% |
| 2000-12-31 | $15.00 Million | $-4.33 Million | -0.289x | +67.98% |
| 1999-12-31 | $3.60 Million | $-3.25 Million | -0.901x | +49.30% |
| 1998-12-31 | $1.80 Million | $-3.20 Million | -1.778x | +70.65% |
| 1997-12-31 | $599.00K | $-3.63 Million | -6.057x | -821.68% |
| 1996-12-31 | $4.06 Million | $-2.67 Million | -0.657x | -268.38% |
| 1995-12-31 | $1.69 Million | $658.00K | 0.390x | -- |
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more